Literature DB >> 20671542

HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.

Christine M Durand1, Karen A O'Connell, Linda G Apuzzo, Susan J Langan, Hejab Imteyaz, Aima A Ahonkhai, Christina M Ceccato, Thomas M Williams, Joseph B Margolick, Joel N Blankson.   

Abstract

We studied viral evolution in five human leukocyte antigen (HLA)-B*57 patients recently infected with HIV-1. Escape mutations in HLA-B*57-restricted Gag epitopes were present at study entry in all patients, but were not associated with significant increases in viremia. Conversely, no new escape mutations in HLA-B*57-restricted epitopes or known compensatory mutations were detected in patients who experienced significant increases in viremia. Thus, the development of escape mutations alone does not determine virologic outcome in recently infected HLA-B*57 patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20671542      PMCID： PMC2941822          DOI： 10.1097/QAD.0b013e32833d8a38

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  19 in total

1.  HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response.

Authors:  Margaret E Feeney; Yanhua Tang; Katja Pfafferott; Kathleen A Roosevelt; Rika Draenert; Alicja Trocha; Xu G Yu; Cori Verrill; Todd Allen; Corey Moore; Simon Mallal; Sandra Burchett; Kenneth McIntosh; Stephen I Pelton; M Anne St John; Rohan Hazra; Paul Klenerman; Marcus Altfeld; Bruce D Walker; Philip J R Goulder
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

2.  HIV-1 evolution following transmission to an HLA-B*5801-positive patient.

Authors:  Karen A O'Connell; Jie Xu; Anna P Durbin; Linda G Apuzzo; Hejab Imteyaz; Thomas M Williams; Stuart C Ray; Joseph B Margolick; Robert F Siliciano; Joel N Blankson
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

3.  Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.

Authors:  Zabrina L Brumme; Chanson J Brumme; Jonathan Carlson; Hendrik Streeck; Mina John; Quentin Eichbaum; Brian L Block; Brett Baker; Carl Kadie; Martin Markowitz; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; John Kaldor; Yuko Yuki; Mary Carrington; Todd M Allen; Simon Mallal; Marcus Altfeld; David Heckerman; Bruce D Walker
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

4.  Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein.

Authors:  Christian L Boutwell; Christopher F Rowley; M Essex
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

5.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

6.  HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Authors:  Toshiyuki Miura; Mark A Brockman; Arne Schneidewind; Michael Lobritz; Florencia Pereyra; Almas Rathod; Brian L Block; Zabrina L Brumme; Chanson J Brumme; Brett Baker; Alissa C Rothchild; Bin Li; Alicja Trocha; Emily Cutrell; Nicole Frahm; Christian Brander; Ildiko Toth; Eric J Arts; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

7.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

Authors:  R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

8.  Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients.

Authors:  Hayley Crawford; Wendy Lumm; Alasdair Leslie; Malinda Schaefer; Debrah Boeras; Julia G Prado; Jianming Tang; Paul Farmer; Thumbi Ndung'u; Shabir Lakhi; Jill Gilmour; Paul Goepfert; Bruce D Walker; Richard Kaslow; Joseph Mulenga; Susan Allen; Philip J R Goulder; Eric Hunter
Journal:  J Exp Med       Date:  2009-03-23       Impact factor: 14.307

9.  The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.

Authors:  Nilu Goonetilleke; Michael K P Liu; Jesus F Salazar-Gonzalez; Guido Ferrari; Elena Giorgi; Vitaly V Ganusov; Brandon F Keele; Gerald H Learn; Emma L Turnbull; Maria G Salazar; Kent J Weinhold; Stephen Moore; Norman Letvin; Barton F Haynes; Myron S Cohen; Peter Hraber; Tanmoy Bhattacharya; Persephone Borrow; Alan S Perelson; Beatrice H Hahn; George M Shaw; Bette T Korber; Andrew J McMichael
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

10.  Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients.

Authors:  Paul A Goepfert; Wendy Lumm; Paul Farmer; Philippa Matthews; Andrew Prendergast; Jonathan M Carlson; Cynthia A Derdeyn; Jianming Tang; Richard A Kaslow; Anju Bansal; Karina Yusim; David Heckerman; Joseph Mulenga; Susan Allen; Philip J R Goulder; Eric Hunter
Journal:  J Exp Med       Date:  2008-04-21       Impact factor: 14.307
View more
  7 in total

1.  Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 subjects.

Authors:  Melissa M Norström; Marcus Buggert; Johanna Tauriainen; Wendy Hartogensis; Mattia C Prosperi; Mark A Wallet; Frederick M Hecht; Marco Salemi; Annika C Karlsson
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

2.  Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Authors:  Clémence Granier; Emilie Battivelli; Camille Lécuroux; Alain Venet; Olivier Lambotte; Marion Schmitt-Boulanger; Constance Delaugerre; Jean-Michel Molina; Lisa A Chakrabarti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

Review 3.  The implications of viral reservoirs on the elite control of HIV-1 infection.

Authors:  Robert W Buckheit; Maria Salgado; Karen O Martins; Joel N Blankson
Journal:  Cell Mol Life Sci       Date:  2012-08-04       Impact factor: 9.261

4.  CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.

Authors:  Christopher W Pohlmeyer; Robert W Buckheit; Robert F Siliciano; Joel N Blankson
Journal:  Retrovirology       Date:  2013-12-12       Impact factor: 4.602

5.  Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy.

Authors:  Guinevere Q Lee; Winnie Dong; Theresa Mo; David J H F Knapp; Chanson J Brumme; Conan K Woods; Steve Kanters; Benita Yip; P Richard Harrigan
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

6.  Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Rebecca T Veenhuis; Megan May; Krystle A Luna; Allison R Kirkpatrick; Oliver Laeyendecker; Andrea L Cox; Mary Carrington; Justin R Bailey; Roberto C Arduino; Joel N Blankson
Journal:  EBioMedicine       Date:  2017-01-26       Impact factor: 8.143

7.  A T Cell Receptor Sequencing-Based Assay Identifies Cross-Reactive Recall CD8+ T Cell Clonotypes Against Autologous HIV-1 Epitope Variants.

Authors:  Hok Yee Chan; Jiajia Zhang; Caroline C Garliss; Abena K Kwaa; Joel N Blankson; Kellie N Smith
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.